Oncolytics Biotech issued new U.S. patent “Reovirus for the Treatment of Neoplasia”
Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma-the most common and deadly brain cancer in humans-that closely resembles the development and progression of human brain tumors that arise naturally. “Mouse models of human cancer have taught us a great deal about the basic principles of cancer biology,”
Full Post: A novel glioblastoma mouse model developed
Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled “Reovirus for the Treatment of Neoplasia.” The patent includes claims to pharmaceutical compositions containing reovirus.
“This U.S. patent expands and strengthens our proprietary position for REOLYSIN(R),” said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. “The pharmaceutical composition claims cover the formulation being used in our ongoing clinical trials.”
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.
Oncolytics Biotech Inc. today announced that it has been granted its 30th U.S. Patent, # 7,452,723, entitled “Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders. “The allowed claims relate to kits comprised of reovirus and an immune suppressive agent that are designed to prevent reovirus recognition by the immune system. “This
Full Post: Oncolytics Biotech issued 30th U.S. patent
neuMirRx Corp today welcomed the issuance of U.S. patent 7,345,093, entitled “Methods for Enhancing Solubility of Compounds” which covers novel formulation methods to enhance the solubility of hydrophobic compounds. The rights to this patent and related proprietary technology, the neuNanoParticle™, have been obtained by neuMirRx Corp through an exclusive license arrangement with Formatech, Inc.
Full Post: neuMirRx issued U.S. patent for “methods for enhancing solubility of compounds
Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids. The aminophospholipid family of phospholipids, including phosphatidylserine (PS), represents a novel target for anti-viral therapies. The new patent follows publication this week
Full Post: Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies
New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives. Dr. Monica Mita of the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health
Full Post: REOLYSIN shown to benefit some sarcoma patients
Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer’s disease and
Full Post: Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists